First Patients Enrolled in Global Phase 2b Study for Adenoviral Conjunctivitis
The first patients have been enrolled in the global
phase 2b clinical study BAYnovation, which will evaluate
the lead compound from NovaBay Pharmaceuticals, Inc.,
NVC-422, for the treatment of adenoviral conjunctivitis,
according to a company news release.
After the FDA provided suggestions on and insight
into the d...